BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 1, 2026
Home » Topics » Regulatory » Patents

Patents
Patents RSS Feed RSS

Neurology/Psychiatric

Otsuka divulges new compounds for ADHD

Feb. 7, 2023
Otsuka Pharmaceutical Co. Ltd. has synthesized hydrogenated quinoxalines acting as serotonin and/or norepinephrine and/or dopamine reuptake inhibitors reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD).
Read More
Cancer

Wigen Biomedicine patents new Wee1 inhibitors for cancer

Feb. 7, 2023
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has disclosed fused ring compounds acting as Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Read More
U.S. Supreme Court

Innovation impact taking center stage in US Supreme Court enablement case

Feb. 6, 2023
By Mari Serebrov
In preparing for their showdown before the U.S. Supreme Court March 27 on what it takes to enable broad genus claims, both Sanofi SA and Amgen Inc. are warning that future innovation will be at stake if the court accepts the other company’s position.
Read More
Cancer

Wigen Biomedicine discovers new DHODH inhibitors for solid and hematologic cancers

Feb. 6, 2023
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has described 1,2,4-triazolone derivatives acting as dihydroorotate dehydrogenase (DHODH) inhibitors reported to be useful for the treatment of solid tumors and hematologic blood cancer.
Read More
Cancer

Humanwell Healthcare describes new TEAD inhibitors for cancer

Feb. 6, 2023
Humanwell Healthcare (Group) Co. Ltd. has identified transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Chinese researchers present new GTPase KRAS (mutant) inhibitors for cancer

Feb. 6, 2023
Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have divulged trideuteromethyl-substituted pyrazino pyrazino quinolinone derivatives acting as deuterated GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.
Read More
Cancer

Biogen and C4 divulge new IRAK-4 degradation inducers

Feb. 6, 2023
Biogen Inc. and C4 Therapeutics Inc. have synthesized proteolysis targeting chimeric (PROTAC) compounds comprising cereblon (CRBN) ligands covalently linked to an IL-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker.
Read More
Cancer

Sichuan Kelun-Biotech patents new KRAS-targeting PROTACS for cancer

Feb. 6, 2023
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a GTPase KRAS (G12D mutant) targeting moiety reported to be useful for the treatment of cancer.
Read More

BioWorld MedTech Patent Highlights: Week 4

From Current Patent Gazette
Feb. 3, 2023
BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patents Gazette.
Read More
Cancer

Kanaph Therapeutics and Yungjin Pharmaceutical identify new PTPN11 inhibitors

Feb. 3, 2023
Kanaph Therapeutics Inc. and Yungjin Pharmaceutical Co., Ltd. have presented tyrosine-protein phosphatase nonreceptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of immunological, cardiovascular, eye disorders, fibrosis, cancer, Noonan syndrome, LEOPARD syndrome and neurofibromatosis type 1.
Read More
Previous 1 2 … 444 445 446 447 448 449 450 451 452 … 3828 3829 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 1, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 30, 2026
  • Illustration demonstrating gut-brain axis

    CINP 2026: Gut microbiota could predict antidepressant response

    BioWorld
    The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
  • Brain made of chip and circuits

    Ascending BCI systems deepen national security, ethical concerns

    BioWorld
    Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
  • Handshake, businessmen holding dollar sign, lightbulb

    Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal

    BioWorld
    A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing